Tag - DXR

Developments

Study with Daxor BVA-100 published in Circulation

Blood volume outcome data has been published in the American Heart Association journal, Circulation, utilizing Daxor’s (NYSE American:DXR) BVA-100 blood volume measurement device to determine the primary endpoint...

May 22, 2020

Feature

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

Daxor’s (NYSE American:DXR) BVA-100 blood volume measurement device is helping to open a new front in the battle against COVID-19. “Optimal volume management and knowledge of capillary status is key to survivability...

April 28, 2020

Markets

Roth starts Daxor at neutral; PT $18

Roth Capital Partners launched coverage of Daxor (NYSE American:DXR) with a “neutral” rating and $18 price target. The stock closed at $9.62 on Sept. 27. Daxor is an investment management company, with a medical device...

September 30, 2019

Tag - DXR

Study with Daxor BVA-100 published in Circulation

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

Roth starts Daxor at neutral; PT $18

General

More